Walleye Capital LLC Makes New $891,000 Investment in Ardent Health, Inc. $ARDT

Walleye Capital LLC bought a new position in shares of Ardent Health, Inc. (NYSE:ARDT) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 90,511 shares of the company’s stock, valued at approximately $891,000. Walleye Capital LLC owned approximately 0.06% of Ardent Health as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of ARDT. Wedge Capital Management L L P NC grew its stake in shares of Ardent Health by 212.3% in the second quarter. Wedge Capital Management L L P NC now owns 327,242 shares of the company’s stock valued at $3,220,000 after acquiring an additional 222,447 shares in the last quarter. Bank of America Corp DE raised its stake in Ardent Health by 11.6% in the 1st quarter. Bank of America Corp DE now owns 361,038 shares of the company’s stock worth $3,090,000 after purchasing an additional 37,627 shares in the last quarter. Amundi bought a new stake in Ardent Health in the 1st quarter valued at about $148,000. The Manufacturers Life Insurance Company boosted its holdings in Ardent Health by 3.7% in the 1st quarter. The Manufacturers Life Insurance Company now owns 29,812 shares of the company’s stock valued at $255,000 after purchasing an additional 1,072 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in Ardent Health by 159.9% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 121,374 shares of the company’s stock valued at $1,039,000 after purchasing an additional 74,675 shares during the period.

Insiders Place Their Bets

In other Ardent Health news, CFO Alfred Lumsdaine acquired 10,000 shares of Ardent Health stock in a transaction that occurred on Friday, June 5th. The shares were acquired at an average cost of $8.81 per share, with a total value of $88,100.00. Following the completion of the purchase, the chief financial officer directly owned 329,183 shares of the company’s stock, valued at $2,900,102.23. This represents a 3.13% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.90% of the stock is owned by company insiders.

Ardent Health Stock Down 0.8%

NYSE ARDT opened at $10.93 on Friday. The business has a fifty day moving average price of $10.21 and a two-hundred day moving average price of $9.58. The stock has a market capitalization of $1.54 billion, a PE ratio of 19.87, a PEG ratio of 3.16 and a beta of 0.70. Ardent Health, Inc. has a fifty-two week low of $7.71 and a fifty-two week high of $15.48. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.10 and a quick ratio of 2.00.

Ardent Health (NYSE:ARDT) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.06). Ardent Health had a net margin of 1.22% and a return on equity of 10.35%. The business had revenue of $1.62 billion during the quarter, compared to the consensus estimate of $1.59 billion. Ardent Health has set its FY 2026 guidance at 0.780-1.150 EPS. Equities analysts expect that Ardent Health, Inc. will post 0.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ARDT shares. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $13.00 target price on shares of Ardent Health in a report on Thursday, August 6th. Royal Bank Of Canada boosted their price target on Ardent Health from $12.00 to $13.00 and gave the company an “outperform” rating in a research note on Monday. Guggenheim upped their price objective on shares of Ardent Health from $13.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. UBS Group increased their price objective on shares of Ardent Health from $13.00 to $13.50 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Finally, Zacks Research lowered shares of Ardent Health from a “hold” rating to a “strong sell” rating in a report on Thursday, August 6th. Seven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $13.05.

Ardent Health Company Profile

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.